Fecal Transplants Beat Standard Care for Chronic Constipation, Study Finds

If you have cycled through laxative after laxative for chronic constipation with only partial relief, you have probably wondered whether the problem lives deeper than your colon, in the trillions of bacteria that call your gut home. A new meta-analysis pooling data from 32 studies and 1,710 patients found that fecal microbiota transplantation (FMT, the transfer of stool from a screened healthy donor into a patient's gut to reset its microbial balance) produced a meaningfully higher clinical response rate than standard treatment alone. The findings, published in Frontiers in Microbiology, are the largest and most methodologically ambitious look yet at whether restoring gut bacteria can help a condition doctors have long managed with fiber, laxatives, and biofeedback. The researchers themselves are candid, though, that the underlying evidence is still shaky, and the caveats matter as much as the headline number.

Fecal Transplant Raises Clinical Response Rate By 21% After Bias Correction

People who received FMT alongside conventional treatment were more likely to see meaningful improvement in their constipation than people who received conventional treatment alone, but the size of that benefit depends on which number you trust. Across seven randomized controlled trials (RCTs) reporting this outcome, the raw pooled result looked large: a risk ratio (RR, how much more likely one group is to respond compared with another) of 1.36 (95% CI: 1.21 to 1.52, involving 535 patients). A statistical check for publication bias, the Harbord test, flagged a problem (P = 0.003): smaller trials with weaker or null results were probably missing from the published literature, inflating the pooled effect. After the researchers used a trim-and-fill technique to estimate and add back those likely-missing studies, the corrected risk ratio came down to 1.21 (95% CI: 1.10 to 1.33), meaning FMT recipients were still about 21% more likely to respond than the control group, just a smaller and more trustworthy margin than the raw number suggested. FMT patients also saw their Wexner score (a 0-30 point clinician-rated scale of constipation severity, where lower is better) fall by an average of 2.08 points more than controls (95% CI: -3.35 to -0.81).

Refractory Constipation Patients Have the Most To Gain

Chronic constipation affects an estimated 12% to 17% of adults worldwide, and it does more than cause discomfort: patients in the studies analyzed here also reported anxiety and depression alongside their bowel symptoms. The condition is often frustrating precisely because standard tools do not always work. First-line laxatives such as polyethylene glycol and lactulose are effective in only 30% to 50% of cases, with high recurrence once people stop taking them, and more invasive options like biofeedback therapy or surgery are either resource-intensive or reserved for severe cases. That gap is why this analysis matters most for people who have already tried the usual laxatives and biofeedback without lasting relief, sometimes labeled "refractory" constipation, since FMT is being explored specifically as an option for that group rather than as a first resort.

A PRISMA-Registered Review Pooled RCTs, Single-Arm Studies, and Cohorts

The review was pre-registered on PROSPERO (an international registry of systematic reviews, ID CRD420261394673) before the researchers began, which reduces the chance of cherry-picking favorable outcomes after the fact, and it followed PRISMA 2020 reporting standards. The team combined three types of evidence in what they called a "three-module" framework: 12 randomized controlled trials (n = 1,040) comparing FMT plus conventional therapy against conventional therapy alone; 16 single-arm studies (n = 403) that tracked FMT patients before and after treatment without a comparison group; and 4 cohort studies (n = 422) comparing different FMT protocols against each other. Among the single-arm studies, 8 (n = 249) reported a combined remission rate of 51.7% and an improvement rate of 67.0%, but because those studies lacked a control group, the researchers were explicit that within-group improvement cannot rule out a placebo effect or people simply getting better over time on their own. FMT was delivered by nasoenteric tube, oral capsule, endoscopy, or colonoscopy across the studies, and a subgroup comparison found no statistically significant difference in effectiveness between delivery routes.

What This Means If You Are Considering FMT for Constipation

For someone managing chronic constipation, especially the refractory kind that has not responded to laxatives, this analysis is a signal that FMT deserves further study, not a green light to seek it out today. FMT for constipation remains an experimental, investigational procedure rather than a standard-of-care option, and every FMT delivery method used in these trials, whether tube, capsule, or endoscopy, requires a clinical setting with a screened donor supply. Attempting a do-it-yourself version outside a medical setting carries real infection risk and is not something this study supports in any way. If you are curious whether FMT might apply to your situation, the reasonable next step is a conversation with a gastroenterologist about whether you would qualify for a clinical trial, not a search for at-home protocols.

Why the Evidence Quality Is Rated Very Low Despite the Result

The headline benefit comes with a serious asterisk. All 12 of the included RCTs were rated high risk of bias, and the dominant reason was not sloppy science but an unavoidable design limit: it is essentially impossible to blind a patient to whether they just received a fecal transplant, so neither patients nor, in most cases, assessors could be kept unaware of which group they were in. That opens the door to placebo effects inflating the perceived benefit, particularly for a subjective symptom like constipation severity. Using the GRADE framework (a standardized system researchers use to rate how much confidence to place in a body of evidence, explained in detail by the CDC), the study authors rated the certainty of evidence for every primary outcome as very low, their lowest possible category. Compounding the concern, all 32 included studies were conducted in China, so it remains unclear whether the results generalize to other populations with different diets, baseline gut microbiomes, and healthcare systems. An earlier randomized trial and a separate meta-analysis on FMT for constipation have reported broadly similar remission and improvement figures, which offers some independent support, though neither resolves the blinding or geographic limitations.

Sham-Controlled Trials Are the Logical Next Step

The study authors are direct about what would settle the question: high-quality, sham-controlled RCTs, trials that give a control group a fake procedure resembling FMT so that neither patients nor assessors can tell which group they are in. That design would separate the biological effect of restoring gut bacteria from the placebo effect of undergoing an invasive-feeling procedure. Safety data are also incomplete: none of the five RCTs that tracked adverse events reported anything serious through follow-up periods of up to 24 weeks, with the most common side effects in the FMT group being bloating, diarrhea, nausea, and gas that resolved on their own. But no study followed patients past 24 weeks, so nothing here speaks to long-term safety.

Common Questions

What is fecal microbiota transplantation? FMT is a medical procedure that transfers stool from a screened, healthy donor into a patient's digestive tract, most often by nasoenteric tube, oral capsule, endoscopy, or colonoscopy, with the goal of restoring a healthier balance of gut bacteria.

Is FMT safe for treating constipation? In this analysis, none of the trials that tracked side effects reported a serious adverse event through 24 weeks of follow-up, and the mild side effects reported (bloating, diarrhea, nausea, gas) resolved on their own, but no study followed patients long enough to assess long-term safety.

How much better did FMT patients do than people on standard treatment? After the researchers corrected for likely publication bias, FMT plus standard treatment was associated with a 21% higher clinical response rate than standard treatment alone (adjusted risk ratio 1.21).

Why does gut bacteria affect constipation in the first place? Dysbiosis, an imbalance in gut bacteria, has been linked to slower colonic transit partly through reduced production of short-chain fatty acids and altered gut-brain signaling, which the authors cite as the biological rationale for trying to reset the microbiome with FMT.

Key takeaways

• A meta-analysis of 32 studies and 1,710 patients found FMT plus standard care raised the clinical response rate for chronic constipation by about 21% compared with standard care alone, after correcting for likely publication bias (adjusted RR 1.21, 95% CI 1.10-1.33).
• No serious adverse events were reported in any trial that tracked safety, through follow-up periods of up to 24 weeks.
• Every included randomized trial was rated high risk of bias because FMT cannot be blinded from patients, the overall certainty of evidence is rated "very low," and all 32 studies were conducted in China, so the findings need confirmation elsewhere before FMT becomes a mainstream option for constipation.

References

1. Zhihong Huang, Zhenwei Dai, Qihong Liu (2026). Efficacy and safety of fecal microbiota transplantation for chronic constipation: a systematic review and meta-analysis integrating pre-post and single-arm evidence. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2026.1900353
2. GRADE Criteria for Determining Certainty of Evidence. cdc.gov. https://www.cdc.gov/acip-grade-handbook/hcp/chapter-7-grade-criteria-determining-certainty-of-evidence/index.html
3. Hongliang Tian, Jianfeng Gong, Ning Li (2016). Capsulized vs Fresh Fecal Microbiota Transplantation in Patients with Slow Transit Constipation: A Randomized Clinical Trial. American Journal of Gastroenterology. https://doi.org/10.14309/00000434-201610001-00542
4. Ke Wang, Chun Gao, Li Zhu, Min Chen, Yi Xin Tong, Sheng Zhang (2025). Fecal microbiota transplantation for chronic constipation: a systematic review and meta-analysis of clinical efficacy, safety, and microbial dynamics. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2025.1604571
5. Toshifumi Ohkusa, Shigeo Koido, Yuriko Nishikawa, Nobuhiro Sato (2019). Gut Microbiota and Chronic Constipation: A Review and Update. Frontiers in Medicine. https://doi.org/10.3389/fmed.2019.00019